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The SA Thoracic Society1 and the Global Initiative for Asthma 
(GINA) have recently published updated guidelines to assist 
practitioners in the management of asthma.2 The guidelines were 
based on reports that asthma management is far from optimal. 
Despite a wealth of evidence on the inflammatory nature of asthma, 
inhaled corticosteroids (ICS) are still under-prescribed and even 
when issued, are under-utilised. Many doctors and patients have also 
aligned themselves to lower expectations: doctors who allow asthma 
to be uncontrolled and patients who accept that they will always 
be symptomatic.The consequences are unnecessary morbidity, 
exacerbations, time off work or school, and even mortality. 
Because the underlying disease process cannot be seen clinically 
until obvious symptoms are present, it tends to be under-assessed 
and therapy is deficient. Until a tool becomes available to measure 
airway inflammation non-invasively and economically (probably 
an exhaled breath analysis device), asthma control will remain 
unsatisfactory. Health professionals need to acquaint themselves 
with the subtleties of asthma and use validated clinical parameters 
to ensure optimal control. 
Experienced faculty members have joined me in this edition to 
discuss these issues and other common scenarios in clinical practice. 
I’ve endorsed the appropriate use of inhaled corticosteroids and 
beta2-adrenoceptor agonists as the mainstay of therapy. When these 
appear insufficient, I need to emphasise that the commonest problem 
encountered in all my experience is poor education on the correct 
technique and optimal use of inhaler devices! This is my most frequent 
intervention in ‘difficult asthmatics’. I’ve often informed patients that 
they could be using the most innovative new molecules or devices, 
usually at considerable expense, but that they would experience no 
therapeutic effect (and it would be wasteful) if the inhalers were 
not used correctly. Patients who, despite attempts at education on 
inhalers, cannot utilise a MDI correctly, or when first-line therapy 
is inadequate, are candidates for leukotriene modifiers and/or 
theophylline. Charles Feldman puts these second-line therapies 
and other specific indications for their use in perspective. John 
O’ Brien discusses diagnostic considerations in the difficult asthmatic 
and the therapeutic approach. Mohamed Gaffar looks at asthma 
in special situations including pregnancy. It must be emphasised 
that the pharmacological control of asthma in pregnancy is more 
important, and that safety concerns over inhaled steroids and beta-
agonists are unnecessary (to date, there are insufficient data on the 
safety of anti-leukotrienes). Exercise-induced asthma is common in 
clinical practice, and Sharon Kling examines various hypotheses and 
treatment.
While the management of adolescent asthma is similar to that of 
adults, young children can be more challenging. Establishing a 
definitive diagnosis, understanding the evolution of wheezing and 
therapy need appropriate refinements. Paul Potter and Robin Green 
explore the current data in this respect.
The differentiation of asthma from chronic obstructive pulmonary 
disease (COPD) is discussed by Michelle Wong and should not 
constitute a diagnostic problem. It is in fact generally true that a 
smoker who develops obstructive lung symptoms has COPD. This 
distinction has become somewhat blurred in recent years due to an 
over-reliance on spirometry for the diagnosis. The demonstration of 
reversible airways obstruction (forced expiratory volume in the first 
second (FEV1) of ≥12% and ≥200 ml change from baseline) has been 
construed to be diagnostic of asthma. This is patently untrue. This 
degree of reversibility is seen in up to 50% of patients with COPD 
and similarly, when asthmatic inflammation is severe or untreated 
it can be difficult to prove reversibility; thus reversible airflow 
limitation is not a diagnostic label. One must emphasise that the 
clinician should have a good idea of the diagnosis from the standard 
pillars of clinical medicine – the history and physical examination 
– before lung function testing, and not after. 
Again, I’ve been concerned that there is possibly an over-emphasis 
on spirometry in COPD in general practice. The technical and 
training requirements for competent and reliable performance 
make this somewhat difficult for the average practitioner. The simple 
Wright’s peak flow meter is still a very useful device and should not 
be underestimated. 
As with all chronic disorders, successful patient outcomes depend 
on the partnership that a doctor can develop with the patient. This is 
particularly true of asthma because of the nuances of the illness and 
the multiple barriers that need to be overcome. Bob Mash discusses 
how the potential of the consultation can be maximised in this 
respect, utilising primary care principles. 
A major departure in the new guidelines is the emphasis on asthma 
control. The previously cumbersome asthma severity classification is 
no longer promulgated. This follows clinical research that has shown 
that asthma can be well or completely controlled with a stepped 
therapeutic approach. The de-emphasis of severity recognises that 
severity is a reflection of both the severity of the disease and the 
response to treatment. Severity also varies over time. Subjects with 
mild disease can be extremely symptomatic and disabled if they’ve 
not been prescribed inhaled corticosteroids, giving the impression of 
disease of a much greater severity. Thus prescriptions appropriately 
tailored to address inflammation, relieve symptoms and normalise 
lung function should achieve control.
On behalf of the SA Thoracic Society, I spearhead an African 
initiative called TASS (Targeting Asthma in Sub-Saharan Africa). I’ve 
met with key opinion leaders from most of these regions. The reader 
will be astonished to learn that in almost all these countries, not a 
single inhaler of any class is available in their public health sectors. 
We are indeed fortunate in South Africa to have considerably better 
resources. The Department of Health has also published asthma 
guidelines for South African health facilities. With this commitment 
we ought to be doing much better. We need to participate actively 
in continuing medical education to be aware of the latest concepts 
which can make a meaningful impact on patient care. 
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Following assimilation of the information in this issue, clinicians 
should have a good idea of how to establish a definitive diagnosis, 
the parameters that constitute well-controlled asthma and how to 
manage asthma in special circumstances. Only then will we have a 
positive influence on the quality of lives of patients and the socio-
economic burden of asthma. 
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